Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Endeavor Biomedicines, Inc.
Eli Lilly and Company
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
Children's Oncology Group
National Cancer Institute (NCI)
Children's National Research Institute
Children's National Research Institute
Taproot Health
National Cancer Institute (NCI)
Emory University
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Washington University School of Medicine
Children's Oncology Group
Emory University
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
MacroGenics
St. Jude Children's Research Hospital
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Emory University
Children's Oncology Group
Celgene
Emory University
Celgene
Nationwide Children's Hospital
St. Jude Children's Research Hospital
National Institutes of Health Clinical Center (CC)
University of Louisville
Dana-Farber Cancer Institute
SillaJen, Inc.
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's National Research Institute
National Cancer Institute (NCI)
Children's Oncology Group
Children's Oncology Group
INSYS Therapeutics Inc
Children's Oncology Group
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)